

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS
Request for Coverage of Chronic Obstructive Pulmonary Disease (COPD) Therapy

PATIENT INFORMATION			
PATIENT SURNAME	PATIENT GIVEN NAME	HEALTH CARD NUMBER	DATE OF BIRTH
PATIENT ADDRESS			
DIAGNOSTIC INFORMATION			
Post bronchodilator-FEV ₁ (% predicted): _____		Post bronchodilator-FEV ₁ /FVC ratio: _____	
MRC Dyspnea Scale Grade: _____			
<input type="checkbox"/> Asthma/COPD (ACO) overlap – Please provide supporting details (patient symptoms, risk factors, spirometry, etc.):			

COPD Assessment Test (CAT) Score _____			
<input type="checkbox"/> Hospitalized for acute severe COPD exacerbation in last 12 months			
<input type="checkbox"/> Two or more moderate COPD exacerbations in the last 12 months requiring antibiotics/systemic corticosteroids			
▶ If spirometry can not be obtained, please provide the details why AND provide the MRC Dyspnea Scale grade to indicate COPD severity:			
Explanation: _____			

REQUESTED THERAPY			
▶ Section 1: Request for Long Acting Beta₂-Agonist (LABA) monotherapy:			
<input type="checkbox"/> Foradil <input type="checkbox"/> Onbrez <input type="checkbox"/> Serevent Diskus			
▶ Section 2: Request for Long Acting Muscarinic Antagonist (LAMA) Monotherapy:			
<input type="checkbox"/> Spiriva Respimat <input type="checkbox"/> Spiriva Handihaler <input type="checkbox"/> Incruse Ellipta <input type="checkbox"/> Seebri Breezhaler <input type="checkbox"/> Tudorza Genuair			
▶ Section 3: Request for Long Acting beta₂-agonist (LABA)/Inhaled Steroid (ICS):			
<input type="checkbox"/> Advair <input type="checkbox"/> Symbicort <input type="checkbox"/> Breo Ellipta			
▶ Section 4: Request for LAMA/LABA dual therapy: (combination of single agent LABA and LAMA will not be considered)			
<input type="checkbox"/> Anoro Ellipta <input type="checkbox"/> Duaklir Genuair <input type="checkbox"/> Inspiolto Respimat <input type="checkbox"/> Ultibro Breezhaler			
<input type="checkbox"/> Has been on a LABA or LAMA for a least 1 month. Inhaler: _____ Start date: _____			
▶ Section 5: Request for LABA/ICS + LAMA or ICS/LAMA/LABA (combined in one inhaler)			
<input type="checkbox"/> Advair <input type="checkbox"/> Symbicort <input type="checkbox"/> Breo Ellipta			
LAMA (please specify) _____			
<input type="checkbox"/> Trelegy Ellipta (Start Date if applicable): _____			
For triple therapy:			
<input type="checkbox"/> Symptomatic despite at least two months of treatment with LABA/ICS or LAMA/LABA.			
Details of prior inhaler therapy:			
Inhaler _____		Start Date: _____	
Inhaler _____		Start Date: _____	
PRESCRIBER NAME & ADDRESS:			
_____		_____	
LICENCE #		PRESCRIBER SIGNATURE	
_____		_____	
		DATE	
_____		_____	

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs
P.O. Box 500, Halifax, NS B3J 2S1
Fax: (902) 496-4440

